{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:39:35Z","timestamp":1784302775935,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2018,5,28]],"date-time":"2018-05-28T00:00:00Z","timestamp":1527465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulinum toxin type A is one of the most useful treatments of sialorrhea in neurological disorders. Evidence for the use of incobotulinumtoxin A (inco-A) in the treatment of sialorrhea is limited. Thirty-six patients with sialorrhea were treated with infiltrations of inco-A into both parotid glands. The severity of sialorrhea was evaluated by the Drooling Severity Scale (DSS), and the Drooling Frequency Scale (DFS). Patients\u2019 perceptions of clinical benefit were recorded via the Patient Global Impression of Improvement (PGI-I) scale. Following treatment, there was a significant difference in both the DFS and the DSS (p &lt; 0.001). Clinical benefits on the basis of the PGI-I were present in up to 90% of patients.<\/jats:p>","DOI":"10.3390\/toxins10060217","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T02:58:18Z","timestamp":1527562698000},"page":"217","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience"],"prefix":"10.3390","volume":"10","author":[{"given":"Javier","family":"Mart\u00ednez-Poles","sequence":"first","affiliation":[{"name":"Department of Neurology, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velina","family":"Nedkova-Hristova","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Bernardo","family":"Escribano-Paredes","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Garc\u00eda-Madrona","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Natera-Villalba","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6855-1093","authenticated-orcid":false,"given":"Carlos","family":"Est\u00e9vez-Fraga","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"},{"name":"Department of Neurodegenerative Diseases, UCL Institute of Neurology, London WC1N 3RX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"L\u00f3pez-Send\u00f3n Moreno","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ic\u00edar","family":"Avil\u00e9s-Olmos","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"S\u00e1nchez D\u00edaz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7744-6850","authenticated-orcid":false,"given":"Juan Carlos","family":"Mart\u00ednez Castrillo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli","family":"Alonso-Canovas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jnnp.70.4.538","article-title":"Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders","volume":"70","author":"Porta","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00415-009-5098-2","article-title":"Prevalence and definition of drooling in Parkinson\u2019s disease: A systematic review","volume":"256","author":"Kalf","year":"2009","journal-title":"J. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/mds.23135","article-title":"Parkinson\u2019s disease symptoms: The patient\u2019s perspective","volume":"25","author":"Politis","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/toxins5051010","article-title":"Sialorrhea: Anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins","volume":"5","author":"Lakraj","year":"2013","journal-title":"Toxins"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.parkreldis.2014.08.013","article-title":"Drooling in Parkinson\u2019s disease: A review","volume":"20","author":"Srivanitchapoom","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/mds.20189","article-title":"Salivary production in Parkinson\u2019s disease","volume":"20","author":"Proulx","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.parkreldis.2007.08.003","article-title":"Is drooling secondary to a swallowing disorder in patients with Parkinson\u2019s disease?","volume":"14","author":"Rodrigues","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2165\/0002512-200825120-00003","article-title":"Sialorrhoea and Drooling in Patients with Parkinson","volume":"25","author":"Merelh","year":"2008","journal-title":"Drugs Ageing"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/mds.23301","article-title":"Silent saliva aspiration in Parkinson\u2019s disease","volume":"26","author":"Rodrigues","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.parkreldis.2007.12.007","article-title":"Is silent aspiration a risk factor for respiratory infection in Parkinson\u2019s disease patients?","volume":"14","author":"Rodrigues","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00415-007-0508-9","article-title":"Impact of drooling in Parkinson\u2019s disease","volume":"254","author":"Kalf","year":"2007","journal-title":"J. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1468-1331.2006.01447.x","article-title":"Botulinum Toxin Treatment of Sialorrhea: Comparing Different Therapeutic Preparations","volume":"13","author":"Tan","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/mds.20793","article-title":"Botulinum toxin type A for drooling in Parkinson\u2019s disease: A double-blind, randomized, placebo-controlled study","volume":"21","author":"Lagalla","year":"2006","journal-title":"Mov. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000439175","article-title":"The Experience of Treating Drooling with Repeated Botulinum Toxin Injections","volume":"77","author":"Numminen","year":"2015","journal-title":"ORL J. Otorhinolaryngol. Relat. Spec."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.3390\/toxins7093758","article-title":"A double-blind randomized controlled trial investigating the most efficacious dose of botulinum toxin-A for sialorrhea treatment in asian adults with neurological diseases","volume":"7","author":"Mazlan","year":"2015","journal-title":"Toxins"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/ane.12559","article-title":"Botulinum toxin-A injections vs. radiotherapy for drooling in ALS","volume":"134","author":"Weikamp","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mds.23929","article-title":"Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson\u2019s disease: A prospective double-blind trial","volume":"27","author":"Chinnapongse","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1212\/01.WNL.0000101713.81253.4C","article-title":"A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson\u2019s disease","volume":"62","author":"Ondo","year":"2004","journal-title":"Neurology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00415-009-0085-1","article-title":"Long-lasting benefits of botulinum toxin type B in Parkinson\u2019s disease-related drooling","volume":"256","author":"Lagalla","year":"2009","journal-title":"J. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.23473","article-title":"Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson\u2019s disease","volume":"26","author":"Guidubaldi","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Sridharan, K., and Sivaramakrishnan, G. (2018). Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials. J. Clin. Neurosci.","DOI":"10.1016\/j.jocn.2018.02.011"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1468-1331.2011.03559.x","article-title":"Five-year experience with incobotulinumtoxinA (Xeomin(\u00ae)): The first botulinum toxin drug free of complexing proteins","volume":"19","author":"Dressler","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00702-017-1767-y","article-title":"Long-term stability of reconstituted incobotulinumtoxinA: How can we reduce costs of botulinum toxin therapy?","volume":"124","author":"Dressler","year":"2017","journal-title":"J. Neural. Transm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2009.02877.x","article-title":"Routine use of Xeomin in patients previously treated with Botox: Long term results","volume":"16","author":"Dressler","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2147\/DDDT.S79193","article-title":"Clinical and pharmacological properties of incobotulinumtoxina and its use in neurological disorders","volume":"9","author":"Jost","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2015-009358","article-title":"Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity: A prospective, non-interventional, open-label, parallel-group study","volume":"5","author":"Dressler","year":"2015","journal-title":"BMJ Open"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Restivo, D.A., Panebianco, M., Casabona, A., Lanza, S., Marchese-Ragona, R., Patti, F., Masiero, S., Biondi, A., and Quartarone, A. (2018). Botulinum toxin a for sialorrhoea associated with neurological disorders: Evaluation of the relationship between effect of treatment and the number of glands treated. Toxins, 10.","DOI":"10.3390\/toxins10020055"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.parkreldis.2016.07.001","article-title":"Drooling in Parkinson\u2019s disease: A randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins","volume":"30","author":"Narayanaswami","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Jost","year":"2006","journal-title":"J. Neural. Transm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jns.2017.08.3244","article-title":"IncobotulinumtoxinA treatment of facial nerve palsy after neurosurgery","volume":"381","author":"Akulov","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/prd.12116","article-title":"The physiology of salivary secretion","volume":"70","author":"Proctor","year":"2016","journal-title":"Periodontology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/mds.10420","article-title":"Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism","volume":"18","author":"Mancini","year":"2003","journal-title":"Mov. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/01.PHM.0000104680.28335.B9","article-title":"Intraparotid Injection of Botulinum Toxin A as a Treatment to Control Sialorrhea in Children with Cerebral Palsy","volume":"83","author":"Savarese","year":"2004","journal-title":"Am. J. Phys. Med. Rehabil."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/10\/6\/217\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:06:15Z","timestamp":1760195175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/10\/6\/217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,28]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["toxins10060217"],"URL":"https:\/\/doi.org\/10.3390\/toxins10060217","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,28]]}}}